Orchard Therapeutics is a holding company. Through its subsidiaries, Co. is a gene therapy company focused on the development of potentially curative gene therapies. Co.'s programs focused on neurodegenerative disorders consist of its commercial program approved in Europe, Libmeldy (OTL-200) for metachromatic leukodystrophy, two clinical proof of concept-stage programs, OTL-203 for mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, and three preclinical programs, OTL-202 for mucopolysaccharidosis type IIIB, OTL-204 for frontotemporal dementia with progranulin mutations and OTL-205 for amyotrophic lateral sclerosis. The ORTX YTD return is shown above.
The YTD Return on the ORTX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ORTX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ORTX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|